Alzheimer's disease (AD) is characterized by progressive neurodegeneration and build-up of A? peptides, amyloid plaques, and neurofibrillary tau tangles. Current strategies to prevent A? formation or secretion are not successful. Preventing A? build-up while enhancing A? uptake and clearance is an alternative approach to minimize the effect of A? peptides. A critical barrier to progress in the development of novel drugs that prevent A? build-up and improve clearance is the lack of a thorough understanding of how A? amyloid plaques are nucleated and proliferate instead of A? being taken up and cleared by glial cells. Our goal is to interrupt amyloid plaque nucleation and propagation to enhance A? clearance and delay the onset and reduce neurodegeneration in AD. Our central hypothesis is that ceramide-enriched exosomes secreted by astrocytes form complexes with A? (A?/Exos) that function as seeds to catalyze nucleation and propagation of neurotoxic plaques instead of facilitating A? transport and clearance by microglia. Secretion, aggregation, and neurotoxicity of A?/Exos is enhanced by elevation of ceramide levels, in particular by neutral sphingomyelinase 2 (nSMase2), an enzyme generating ceramide when activated by A?. Drug (e.g., nSMase2 inhibitor)-induced reduction of ceramide will prevent A?/Exo build-up/spreading and protect neurons, which is a novel treatment option for AD. Our objectives are to 1) test key regulatory factors that control secretion of exosomes and their association with A?; 2) test a novel molecular mechanism by which A?/Exos induce plaque formation, tau hyperphosphorylation, and neuronal cell death; 3) test pharmacological drugs that prevent exosome secretion, A?/Exo-induced plaque formation, tau hyperphosphorylation, and neuronal cell death in vitro and in vivo; and 4) test if A?/Exos in serum and cerebrospinal fluid from AD model mice and AD patients can be used as a novel diagnostic tool for monitoring plaque and tangle build-up, and treatment success. Our expected outcomes include 1) determining an exosome composition that induces association with A?, plaque nucleation and propagation, tau hyperphosphorylation, and neuronal cell death; 2) identifying ceramide- modulating drugs that prevent A?/Exo-induced plaque formation, tau hyperphosphorylation, and neuronal cell death; and 3) defining a level of A?/Exos in serum that indicates severity of AD and success of treatment. The impact of this project on public health will include knowledge needed for the development of new strategies and treatments that could delay and reduce the onset of progressive neurodegeneration in AD. We will test by which mechanism ceramide promotes association and aggregation of A?42 (Aim 1), how A?42/Exos induce plaque formation and neurodegeneration (Aim 2), and which treatment prevents exosome-induced amyloid aggregation, plaque formation, and AD pathology (Aim 3).

Public Health Relevance

Development of novel drugs to treat Alzheimer's disease (AD) by preventing amyloid plaque formation and neurodegeneration is being impeded by lack of knowledge of how neurotoxic plaques are nucleated and propagated. Our goal is to interrupt amyloid plaque nucleation and propagation to enhance amyloid peptide clearance and delay the onset and reduce neurodegeneration in AD. The impact of this project on public health will include knowledge needed for the development of new strategies and treatments that could delay and/or reduce the onset of progressive neurodegeneration in Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG034389-09
Application #
9626065
Study Section
Cellular and Molecular Biology of Glia Study Section (CMBG)
Program Officer
Yang, Austin Jyan-Yu
Project Start
2010-09-01
Project End
2021-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
9
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Physiology
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40526
Burgert, Anne; Schlegel, Jan; Bécam, Jérôme et al. (2017) Characterization of Plasma Membrane Ceramides by Super-Resolution Microscopy. Angew Chem Int Ed Engl 56:6131-6135
Yue, Hai-Yuan; Bieberich, Erhard; Xu, Jianhua (2017) Promotion of endocytosis efficiency through an ATP-independent mechanism at rat calyx of Held terminals. J Physiol 595:5265-5284
Helwa, Inas; Cai, Jingwen; Drewry, Michelle D et al. (2017) A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents. PLoS One 12:e0170628
Spassieva, Stefka; Bieberich, Erhard (2016) Lysosphingolipids and sphingolipidoses: Psychosine in Krabbe's disease. J Neurosci Res 94:974-81
Walter, T; Collenburg, L; Japtok, L et al. (2016) Incorporation and visualization of azido-functionalized N-oleoyl serinol in Jurkat cells, mouse brain astrocytes, 3T3 fibroblasts and human brain microvascular endothelial cells. Chem Commun (Camb) 52:8612-8614
Spassieva, Stefka D; Ji, Xiaojie; Liu, Ye et al. (2016) Ectopic expression of ceramide synthase 2 in neurons suppresses neurodegeneration induced by ceramide synthase 1 deficiency. Proc Natl Acad Sci U S A 113:5928-33
Dinkins, Michael B; Enasko, John; Hernandez, Caterina et al. (2016) Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. J Neurosci 36:8653-67
Kong, Ji Na; He, Qian; Wang, Guanghu et al. (2015) Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells. Int J Cancer 137:1610-20
Dinkins, Michael B; Dasgupta, Somsankar; Wang, Guanghu et al. (2015) The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden. J Alzheimers Dis 46:55-61
Dinkins, Michael B; Dasgupta, Somsankar; Wang, Guanghu et al. (2014) Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 35:1792-800

Showing the most recent 10 out of 19 publications